Business Wire

Gilead Announces Latest Data in Ongoing HIV Cure Research Program

Share

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City.

“While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These findings demonstrate that TLR7 agonists have a potential role to play in scalable strategies for achieving sustained viral remission in humans, and we will continue to evaluate these agents as part of investigational curative regimens.”

Studies on TLR7 agonists presented at IAS include:

Oral presentation WEAA0304: Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals

This double-blind, placebo-controlled Phase 1 clinical study enrolled 48 people living with HIV on antiretroviral therapy. The median age of the participants in this study was 47 years (43 were male), with a median of 8.1 years of therapy. In the study, 36 participants received escalating doses of vesatolimod (1-12 mg) and 12 received placebo every other week. Vesatolimod at higher doses stimulated a range of immune responses. Vesatolimod was well-tolerated at all doses, with no drug-related Grade 3 or 4 adverse events, no related serious adverse events and no adverse events leading to study drug discontinuation. Study drug-related adverse events including mild, transient flu-like symptoms were observed in 9 of 36 participants at doses of 2 mg and higher, consistent with previous trials. These symptoms resolved within one day and did not occur with each dose.

“This study demonstrates that vesatolimod can be administered to people living with HIV at doses that may have immune effect and are well-tolerated. The results support studies into the potential role of vesatolimod as part of combination regimens aimed at achieving ART-free control of HIV,” said Sharon A. Riddler, MD, Director of Clinical Research in the Infectious Diseases Division, University of Pittsburgh School of Medicine, one of the study principal investigators.

Oral presentation WEAA0105: Oral TLR7 agonist administration induces an immunostimulatory response in SIV-infected ART-suppressed infant rhesus macaques

This preclinical study evaluated the oral administration of GS-986 in two simian immunodeficiency virus (SIV)-infected, virologically suppressed rhesus macaques. At seven months of age, both macaques were administered 0.1 mg of GS-986 orally. Four weeks later, a second 0.3 mg dose was administered, and in both instances blood count, viral loads, cytokine concentrations and immune response were monitored. At both the 0.1 mg and 0.3 mg dose levels, GS-986 induced immune system activation with observed increases in peripheral plasma cytokines/chemokines and activation of immune cells. GS-986 was well-tolerated with normal complete blood count and maintenance of viral suppression.

These results add new information to the existing preclinical data on GS-986 for the potential future application of an oral TLR7 agonist in people living with HIV.

Vesatolimod and GS-986 are investigational compounds and are not approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established.

There is no cure for HIV infection or AIDS.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it is estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving GS-9620 and GS-986. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Sung Lee, Investors
(650) 524-7792

Ryan McKeel, Media
(650) 377-3548

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Walgreens Boots Alliance and McKesson to Create German Wholesale Joint Venture12.12.2019 09:00:00 CETPress release

Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) today signed an agreement to create a joint venture that will combine their respective pharmaceutical wholesale businesses in Germany, Alliance Healthcare Deutschland and GEHE Pharma Handel. WBA will have a 70% controlling equity interest in the joint venture and McKesson will have a 30% ownership interest. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005230/en/ The new joint venture is expected to enhance the ability to compete and deliver high customer satisfaction through new services and operational excellence, ultimately advancing patient-centric solutions. In addition, the combined business will deliver efficient distribution solutions, and drive greater economies of scale, stimulating the competitiveness of the German pharmaceutical wholesale market. The transaction does not include any other WBA or McKesson businesses outside of the G

Indirect Tax Expert Peter Boerhof Joins Vertex12.12.2019 08:30:00 CETPress release

Vertex, Inc., a leading provider of tax technology solutions, announced that Peter Boerhof has joined as VAT director in Europe. Boerhof joins Vertex from AkzoNobel where he was responsible for leading the global indirect tax function. He has extensive experience in international transactions, business restructuring, merger and acquisition, tax process optimization and tax automation. Unique in the tax technology industry, Vertex's Chief Tax Office (CTO) provides insight regarding the impact of tax regulations, policy, enforcement and emerging technology trends on global tax department operations. The Vertex CTO group consists of former tax executives from various Fortune 500 multinationals, who bring their in-house tax and industry expertise to Vertex's solution development, services and customer interactions. “We welcome Peter, who has extensive experience in global tax operations, including customs, VAT and relationship management with international tax administrations,” stated Vert

Kioxia Develops New 3D Semicircular Flash Memory Cell Structure “Twin BiCS FLASH”12.12.2019 07:37:00 CETPress release

Kioxia Corporation today announced the development of the world’s first[1] three-dimensional (3D) semicircular split-gate flash memory cell structure “Twin BiCS FLASH” using specially designed semicircular Floating Gate (FG) cells. Twin BiCS FLASH achieves superior program slope and a larger program/erase window at a much smaller cell size compared to conventional circular Charge Trap (CT) cells. These attributes make this new cell design a promising candidate to surpass four bits per cell (QLC) for significantly higher memory density and fewer stacking layers. This technology was announced at the IEEE International Electron Devices Meeting (IEDM) held in San Francisco, CA on December 11th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191211006038/en/ Fabricated semicircular FG cells (a) Cross-sectional view (b) Plane view (Graphic: Business Wire) 3D flash memory technology has achieved high bit density with low cost per b

BIOCORP and SANOFI Announce a Partnership to Fit SoloStar Insulin Pens With Mallya Technology Worldwide12.12.2019 06:30:00 CETPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a worldwide partnership agreement with SANOFI for the use of Mallya technology, a connected device for insulin pens. This long-term agreement is the first decision resulting from exclusive negotiations initiated in July 2019. SANOFI and BIOCORP are thus fulfilling today their ambition to enter into a long-term partnership in the diabetes area. The agreement covers two main points: - Sanofi acquires the rights to a non-exclusive distribution of Mallya in its current version worldwide, starting in 2020. - BIOCORP is committed to develop a specific and exclusive version of Mallya for SoloStar, SANOFI's insulin pen. As a result of the agreement, Sanofi is to pay BIOCORP a further €2 million upon signature of the contract (last July, BIOCORP received a first pa

IFF Declares Dividend for Fourth Quarter 201911.12.2019 21:15:00 CETPress release

Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent and nutrition announced that its Board of Directors has declared a regular quarterly cash dividend of $0.75 per share of its common stock, payable on January 7, 2020 to shareholders of record as of December 27, 2019. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005907/en/ Contact information Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com

Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy11.12.2019 21:05:00 CETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. “There remains a significant need